CD274 and cancer: KKU100 with the moderate PD-L1 expression (~ 40–50%), which greatly responded to gemcitabine treatment (Supplementary Fig. 1B) was selected to study the effect of PD-L1xCD3 BiTE in the model of cancer spheroid.